Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2345/0899-8205-51.6.508 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An Overview of Invasive Ductal Carcinoma (IDC) in Women's Breast Cancer.
Curr Mol Med
January 2025
Division of Biological and Health Sciences, University of Pittsburgh, 300 Campus Drive, Bradford PA 16701.
Invasive ductal carcinoma (IDC) is the most common type of breast cancer, primarily affecting women in the United States and across the world. This review summarizes key concepts related to IDC causes, treatment approaches, and the identification of biological markers for specific prognoses. Furthermore, we reviewed many studies, including those involving patients with IDC and ductal carcinoma in situ (DCIS) that progressed to IDC.
View Article and Find Full Text PDFAssessing quality of health care in the context of patient satisfaction from patients' perspective among a physical therapy and rehabilitation unit.
BMC Health Serv Res
January 2025
Balikesir Ataturk City Hospital, PM&R Clinic, Balikesir, Turkey.
Health service policies are evolving into qualified health care providing best possible outcomes as well as focused on patient satisfaction. Hence the qualification valued health care includes patient satisfaction measurements, it is suggested to get feedbacks during the assessment of outcomes from the patient's perspective. Aging of the world population accelerates demand on rehabilitation medicine which means recovering impairments so is directly related with quality of life.
View Article and Find Full Text PDFIdentifying Cladribine prescription pattern in MS: an Italian multicentre study.
Ther Adv Neurol Disord
January 2025
Department of Medical and Surgical Sciences, University of Foggia, Foggia 71122, Italy.
Background: Characterizing Cladribine tablets prescription pattern in daily clinical practice is crucial for optimizing multiple sclerosis (MS) treatment.
Objectives: To describe efficacy, safety profile and new disease-modifying therapy (DMT) prescriptions following Cladribine treatment.
Design: Independent retrospective cohort study in patients followed at six Italian MS centres.
A Cross-Sectional Study of Non-communicable Disease Risk Factors Among Non-diabetic and Non-hypertensive Population.
Cureus
December 2024
Community Medicine, Bharati Vidyapeeth (Deemed to be University) Medical College and Hospital, Sangli, IND.
Introduction: Noncommunicable diseases, especially diabetes and hypertension, have emerged as significant public health challenges. Regular screening, even among healthy individuals, is essential for early diagnosis and prevention of complications.
Methods: This cross-sectional study was conducted in an urban ward of the Sangli-Miraj-Kupwad municipal corporation in Maharashtra, India, and cluster random sampling was used to collect data.
A Tertiary Centre's Experience With Using Ranibizumab Biosimilar Compared to Aflibercept for Neovascular Age-Related Macular Degeneration: A Retrospective Study.
Cureus
December 2024
Ophthalmology, University Hospital of Wales, Cardiff, GBR.
Objective This study aims to evaluate the real-world efficacy of ranibizumab biosimilar (Ongavia), compared to aflibercept (Eylea), in the treatment of treatment-naïve neovascular age-related macular degeneration (nAMD) at a busy tertiary eye care centre. Methods A retrospective analysis of medical records from August 2022 to August 2024 was conducted, comparing treatment outcomes in treatment-naive nAMD patients who received either Ongavia or Eylea intravitreal anti-VEGF (vascular endothelial growth factor) injections under a treat-and-extend protocol. Initial and 12-month outcome measures post-treatment initiation were collected, including best-corrected visual acuity (BCVA), central retinal thickness (CRT), prescribed treatment intervals, actual injection frequency, and the average total number of injections per eye over 12 months.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!